Want to see AMWL full AI Analyst Report?
Top Page
American Well
(NYSE:AMWL)
Select Model
Select Model
Rating:55Neutral
Price Target:
$9.50
▲(55.23% Upside)
Action:Reiterated
Date:06/23/26
AMWL scores mid-range primarily due to weak financial performance (ongoing losses and negative free cash flow) despite a low-debt balance sheet and improving loss trends. Technicals are moderately supportive (longer-term uptrend with positive MACD), while valuation remains challenged by unprofitability and no dividend. The latest earnings call improves the outlook on cost discipline and cash flow trajectory, but persistent revenue and platform-usage declines keep risk elevated.
Positive Factors
Low Leverage / Strong Balance Sheet
Extremely low leverage provides durable financial flexibility: with minimal debt the company can fund operations, absorb continued losses, or pursue strategic investments without near-term refinancing risk. This structural strength lengthens runway while management executes on profitability.
Negative Factors
Declining Revenue
Sustained top-line declines weaken operating leverage and long-term margin sustainability. If revenue contraction continues, fixed-cost absorption and progress toward break-even are jeopardized, forcing deeper cuts or dependence on balance-sheet resources to maintain operations and strategic initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Extremely low leverage provides durable financial flexibility: with minimal debt the company can fund operations, absorb continued losses, or pursue strategic investments without near-term refinancing risk. This structural strength lengthens runway while management executes on profitability.
Read all positive factors
American Well Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down revenue across different business segments, providing insight into which areas are driving growth and where the company might be facing challenges or opportunities for expansion.
Breaks down revenue across different business segments, providing insight into which areas are driving growth and where the company might be facing challenges or opportunities for expansion.
Data provided by:
The Fly
The FlyAmerican Well (AMWL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$144.86M
Dividend YieldN/A
Average Volume (3M)94.74K
Price to Earnings (P/E)―
Beta (1Y)2.02
Revenue Growth-9.29%
EPS Growth46.89%
CountryUS
Employees562
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-5.42
Shares Outstanding15,061,188
10 Day Avg. Volume80,702
30 Day Avg. Volume94,738
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.32
P/FCF Ratio-1.19
Enterprise Value/Market Cap-0.23
Enterprise Value/Revenue-0.14
Enterprise Value/Gross Profit-0.28
Enterprise Value/Ebitda0.63
Forecast
1Y Price Target
$7.50Price Target Upside22.55% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-3.38
Revenue Forecast (FY)$201.98M
American Well Business Overview & Revenue Model
Company Description
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Amwell Platform, a cloud-based enablement platform, digitally enables a sc...
How the Company Makes Money
Amwell primarily makes money by selling access to its telehealth software platform and related services to organizations. Key revenue streams include: (1) Subscription revenue: recurring fees paid by customers to use Amwell’s telehealth platform a...
American Well Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call conveyed balanced but constructive progress: clear operational and cost improvements drove meaningful profitability trajectory (adjusted EBITDA and operating loss improvement), a stronger recurring revenue mix, sizable pipeline expansion, and government/customer validations (Elevance renewal, DHA deployment). Offsetting these positives were continued top-line headwinds—total revenue down ~18%, subscription revenue down ~23%, and total platform visits down ~19%—and the company remains unprofitable on a GAAP basis for 2026. Management's guidance (narrowed adjusted EBITDA loss range), strong cash position, reduced cash burn, and confidence in reaching cash flow breakeven in Q4 2026 tilt the overall tone optimistic despite near-term revenue and usage declines.Positive Updates
Improved Profitability and Operating Performance
Adjusted EBITDA loss improved to -$3.1M in Q1 2026 from -$12.2M in Q1 2025 (a $9.1M improvement). Operating loss improved ~43% year-over-year to -$17.4M from -$30.4M.
Negative Updates
Revenue Decline
Total revenue for Q1 2026 was $54.9M, down ~18% year-over-year, reflecting portfolio changes and previously disclosed churn.
Read all updates
Q1-2026 Updates
Positive
Negative
Improved Profitability and Operating Performance
Adjusted EBITDA loss improved to -$3.1M in Q1 2026 from -$12.2M in Q1 2025 (a $9.1M improvement). Operating loss improved ~43% year-over-year to -$17.4M from -$30.4M.
Read all positive updates
Company Guidance
Amwell's guidance called for Q2 2026 revenue of $48–52 million and an adjusted EBITDA loss of $(4)–$(2) million (citing normal seasonality and step-down in subscription revenue), while the full‑year 2026 outlook was reiterated at $195–205 million of revenue with a narrowed adjusted EBITDA loss of $(16)–$(12) million (previously $(24)–$(18)M); management reiterated a path to positive operating cash flow in Q4. These targets were informed by Q1 results: revenue $54.9M (−18% YoY), subscription revenue $24.9M (−23% YoY), AMG visit revenue $28.9M (+9% YoY) with ~382k AMG paid visits and revenue per visit ≈ $76 (+$5 YoY), total platform visits ≈ 1.0M (−19% YoY), gross profit $28M and gross margin 51% (−180 bps YoY), operating expenses $45.4M (−31% YoY; 82.6% of revenue vs 98.3% prior), adjusted EBITDA loss $(3.1)M (vs $(12.2)M prior), operating loss $(17.4)M (vs $(30.4)M), cash burn ≈ $3.1M this quarter (vs $19M prior), and ending cash & investments of ≈ $179M with zero debt.American Well Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 237.38M | 249.32M | 254.36M | 259.05M | 277.19M | 252.79M |
| Gross Profit | 118.00M | 132.86M | 98.95M | 94.76M | 116.77M | 104.31M |
| EBITDA | -53.01M | -60.57M | -176.91M | -224.15M | -245.84M | -166.07M |
| Net Income | -87.88M | -95.70M | -208.14M | -675.16M | -270.43M | -176.33M |
Balance Sheet | ||||||
| Total Assets | 325.97M | 323.79M | 435.97M | 589.71M | 1.22B | 1.45B |
| Cash, Cash Equivalents and Short-Term Investments | 179.21M | 182.33M | 228.32M | 372.04M | 538.55M | 746.42M |
| Total Debt | 3.96M | 4.52M | 8.20M | 11.79M | 14.84M | 16.61M |
| Total Liabilities | 85.84M | 76.00M | 119.72M | 109.52M | 133.71M | 184.96M |
| Stockholders Equity | 227.33M | 235.58M | 304.77M | 464.22M | 1.06B | 1.24B |
Cash Flow | ||||||
| Free Cash Flow | -41.84M | -65.97M | -142.56M | -163.59M | -202.77M | -142.10M |
| Operating Cash Flow | -41.83M | -65.95M | -127.34M | -148.34M | -192.32M | -141.54M |
| Investing Cash Flow | -5.07M | 17.10M | -18.65M | -19.17M | -11.63M | -59.63M |
| Financing Cash Flow | 600.00K | 840.00K | 1.38M | 2.15M | -3.61M | 5.75M |
American Well Technical Analysis
Positive
6.12
Price Trends
8.26
Positive
6.94
Positive
5.92
Positive
Market Momentum
0.23
Positive
56.28
Neutral
46.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMWL, the sentiment is Positive. The current price of 6.12 is below the 20-day moving average (MA) of 8.83, below the 50-day MA of 8.26, and above the 200-day MA of 5.92, indicating a bullish trend. The MACD of 0.23 indicates Positive momentum. The RSI at 56.28 is Neutral, neither overbought nor oversold. The STOCH value of 46.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMWL.
American Well Risk Analysis
American Well disclosed 10 risk factors in its most recent earnings report. American Well reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
American Well Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $115.41M | 17.14 | 5.47% | ― | 13.75% | ― | |
61 Neutral | $1.64B | -9.49 | -12.37% | ― | -1.50% | 83.75% | |
55 Neutral | $144.86M | -1.68 | -35.14% | ― | -9.29% | 46.89% | |
53 Neutral | $629.89M | -1.20 | -77.89% | ― | -21.26% | -290.08% | |
52 Neutral | $162.57M | -0.60 | -99.78% | ― | -2.83% | -223.32% | |
52 Neutral | $116.71M | -0.49 | -67.07% | ― | -3.89% | 63.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
AMWL
American Well
9.12
0.73
8.70%
OPRX
OptimizeRx
6.28
-7.00
-52.71%
EVH
Evolent Health
5.63
-5.60
-49.87%
TDOC
Teladoc
9.21
0.40
4.54%
HCAT
Health Catalyst
2.24
-1.75
-43.86%
DH
Definitive Healthcare Corp
0.80
-3.38
-80.86%
American Well Corporate Events
Executive/Board ChangesShareholder Meetings
American Well Shareholders Back Board, Auditor and Pay
Positive
Jun 22, 2026
American Well Corporation held its 2026 annual meeting of stockholders on June 16, 2026, where shareholders elected Class III director Dr. Ido Schoenberg to serve on the board until the 2029 annual meeting, following the previously disclosed decis...
Executive/Board Changes
American Well Co-Founder and Executive Vice Chairman Departs Board
Neutral
May 12, 2026
On May 6, 2026, American Well Corporation announced that co-founder and Executive Vice Chairman Dr. Roy Schoenberg resigned from its Board of Directors, effective immediately, to pursue a new employment opportunity. The company emphasized that his...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.